Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12488733 | 1.00 | KMT2A (0.74) | KMT2AMEN1TSHRLMNAKDM4E | |
| SCHEMBL215293 | 0.97 | — | — | |
| Fluoride SCHEMBL28145644 | 0.95 | KMT2A (0.67) | KMT2AMEN1TSHRLMNAKDM4E | |
| Sulfuric Acid SCHEMBL30521460 | 0.89 | KMT2A (0.59) | KMT2AMEN1TSHRLMNAKDM4E | |
| Phosphoric Acid SCHEMBL30521627 | 0.89 | KMT2A (0.59) | KMT2AMEN1TSHRLMNAKDM4E | |
| Hydrochloric Acid SCHEMBL1671482 | 0.86 | MEN1 (0.61) | KMT2AMEN1TSHRLMNAKDM4E | |
| SCHEMBL713902 | 0.83 | TSHR (0.64) | KMT2AMEN1TSHRLMNAKDM5A | |
| SCHEMBL5788270 | 0.82 | KMT2A (0.95) | KMT2AMEN1TSHRLMNAKDM4E | |
| SCHEMBL10084980 | 0.81 | TSHR (0.61) | KMT2AMEN1TSHRLMNAKDM5A | |
| SCHEMBL15782634 | 0.81 | MEN1 (0.55) | KMT2AMEN1TSHRLMNAKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060293372-A1 | Beta-sheet mimetics and methods relating to the use thereof | MYRIAD GENETICS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| US-7125872-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1661566-A2 | Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors | MYRIAD GENETICS, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-0915700-B1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MYRIAD GENETICS INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040230035-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699869-B1 | PROTEASE INHIBITORS, ANTICOAGULANT | MYRIAD GENETICS INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030191109-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | KAHN MICHAEL (US) | 2003-10-09 | — | — | US | disclosed |
| US-6586426-B1 | Pyrrolizine derivatives; thrombin, elastase, and factor X inhibitors | MOLECUMETICS LTD. | 2003-07-01 | — | — | US | disclosed |
| US-20030027819-A1 | Beta-sheet mimetics and methods relating to the use thereof | MOLECUMETICS LTD. | 2003-02-06 | — | — | US | disclosed |
| EP-1053246-B1 | BETA-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF | MOLECUMETICS LTD (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6372744-B1 | PROTEASE OR KINASE INHIBITORS | MOLECUMETICS LTD. | 2002-04-16 | — | — | US | disclosed |
| EP-0815123-B1 | BETA-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS | MOLECUMETICS LTD (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6245764-B1 | PROTEASE INHIBITORS; ANTICANCER AGENTS; IMMUNOLOGY CONTROLLERS; ANTIINFLAMMATORY AGENTS | MOLECUMETICS LTD. | 2001-06-12 | — | — | US | disclosed |
| US-6117896-A | Methods for regulating transcription factors | MOLECUMETICS LTD. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6020331-A | β-sheet mimetics and use thereof as protease inhibitors | MOLECUMETICS, LTD. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0915700-A1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MOLECUMETICS, LTD. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998005333-A1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MOLECUMETICS LTD. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027819-A1 | Beta-sheet mimetics and methods relating to the use thereof | SERBP1, HGFAC, PACSIN2 | GAA 963/4885CHRM2 4792/4885CHRM4 4738/4885 |
| US-20060293372-A1 | Beta-sheet mimetics and methods relating to the use thereof | SERBP1, PACSIN2, HGFAC | GAA 803/4885CHRM2 4797/4885CHRM4 4763/4885 |
| US-20030191109-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MICA, BMX, CD74 | GAA 1064/4885CHRM2 4539/4885CHRM4 4662/4885 |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | GAA 879/4885CHRM2 4700/4885CHRM4 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.